In this webinar, the NS Pharma team presents updates for the Duchenne community:
- Access programs for Viltepso, which is suitable for individuals with Duchenne who are amenable to exon 53 skipping
- The upcoming clinical trial for individuals with Duchenne who are amenable to exon 44 skipping
- Future plans in Duchenne, including exon skipping programs targeting exons 50, 51, 45 and 55
You’ll be prompted to enter your name and email address to view the recording.
Judy Cohen is a Patient Engagement Lead (PEL) at NS Pharma and works closely with patients and caregivers across the U.S. helping them overcome barriers to accessing treatments. Judy joined NS Pharma in 2020 and leverages her passion, expertise and background in healthcare to help patients impacted by rare diseases.
Jonathan Cabral has over 30 years of experience in the biotechnology industry and has a passion for working with start-ups developing breakthrough medications. During this time, he has been involved in helping bring to market a dozen new medications several for autoimmune or rare diseases. He has worked across several functional areas including patient advocacy, patient services, sales, marketing, and market access.
Jay Chauhan is a Medical Science Liaison (MSL) at NS Pharma, responsible for engaging with neuromuscular specialists to advance the treatment landscape for Duchenne Muscular Dystrophy (DMD). Joining NS Pharma in 2021, Dr. Chauhan utilizes his Doctor of Pharmacy (PharmD) education to communicate scientific information from a medical perspective and is passionate in collaborating with the DMD community to provide an opportunity for patients to overcome their rare disease.